The next decade of vaccines: societal and scientific challenges (Q39740365)

14 September 2017

The next decade of vaccines: societal and scientific challenges (English)

1 reference

14 September 2017

2

Claire-Anne Siegrist

1 reference

14 September 2017

E Richard Moxon

1

1 reference

PubMed ID

21664685

14 September 2017

language of work or name

English

0 references

publication date

12 June 2011

1 reference

14 September 2017

1 reference

14 September 2017

378

1 reference

14 September 2017

9788

1 reference

14 September 2017

348-359

1 reference

Vaccine discovery and translation of new vaccine technology

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Vaccine production, distribution, access, and uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

The future of immunisation policy, implementation, and financing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Studies on variants of poliomyelitis virus. I. Experimental segregation and properties of avirulent variants of three immunologic types

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Nothing in Biology Makes Sense except in the Light of Evolution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

VARIATION AND TYPE SPECIFICITY IN THE BACTERIAL SPECIES HEMOPHILUS INFLUENZAE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

No evidence for Haemophilus influenzae serotype replacement in Europe after introduction of the Hib conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Quadrivalent meningococcal conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Global epidemiology of meningococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in Niger

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Review of meningococcal group B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Serotype-specific problems associated with pneumococcal conjugate vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Population structure of pathogens: the role of immune selection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

An HIV vaccine--challenges and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Immunology and the elusive AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

AIDS/HIV. A boost for HIV vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Antigenic variation at the infected red cell surface in malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Urbanization, malaria transmission and disease burden in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

A universal vaccine for serogroup B meningococcus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Dengue: a continuing global threat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Cross-reacting antibodies enhance dengue virus infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

EstimatingHaemophilus influenzaeType b Vaccine Effectiveness in England and Wales by Use of the Screening Method

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Estimation of vaccine effectiveness using the screening method.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

B-cell responses to vaccination at the extremes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Implication of gut immunology in the design of oral vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Vaccinology in the genome era.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Regulation of CD4 T-cell receptor diversity by vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Duration of antiviral immunity after smallpox vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Generating memory with vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Programming the magnitude and persistence of antibody responses with innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Booster vaccinations: can immunologic memory outpace disease pathogenesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Pneumococcal vaccination of elderly adults: new paradigms for protection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Impact of the quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Update on universal annual influenza immunization recommendations for children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

The continuing tensions between individual rights and public health. Talking Point on public health versus civil liberties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Innate immunity of the newborn: basic mechanisms and clinical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Live attenuated versus inactivated influenza vaccine in infants and young children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Vaccines for preventing influenza in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Efficacy of pneumococcal vaccination in adults: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Vaccines for preventing pneumococcal infection in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Vaccination in the elderly: an immunological perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Influenza vaccines provide diminished protection but are cost-saving in older adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Molecular and cellular signatures of human vaccine adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Oral rotavirus vaccines: how well will they work where they are needed most?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Human genetics of infectious diseases: between proof of principle and paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

The prevention of infection-associated cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Application of pharmacogenomics to vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Reverse vaccinology: developing vaccines in the era of genomics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

1 reference

7 January 2021

Vaccination and risk groups: how can we really protect the weakest?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

Host-bacterial symbiosis in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960407-8

7 January 2021

10.1016/S0140-6736(11)60407-8

Identifiers

DOI

1 reference

14 September 2017

1 reference

PubMed ID

21664685